Wuxi Pharmatech (Cayman) Inc., of Shanghai, said it established a representative office in the Tel Aviv area of Israel, aimed at promoting Wuxi's platform of integrated R&D services to local customers. It also will collaborate with Pontifax, a health care-dedicated venture capital firm based in Israel, to invest in technologies in the region, particularly those that can advance Wuxi's capabilities. Read More

TAIPEI, Taiwan – Twi Biotechnology Inc., the drug development arm of Taipei, Taiwan-headquartered generics firm Twi Pharmaceutical Inc., recently received orphan drug designation from the FDA for the use of its AC-201 drug candidate to topically treat epidermolysis bullosa (EB). With that new indication, AC-201 is currently under development by Twi in three tracks: type 2 diabetes, gout and now for EB, a debilitating skin condition. Read More

HONG KONG – After years of waiting, Chinese biosimilar makers will soon have a comprehensive set of guidelines to follow, likely tipping the scales to make the massive country one of the top markets for biosimilars. Read More

HONG KONG – Researchers from the Li Ka Shing Faculty of Medicine at The University of Hong Kong (HKU) have developed a DNA vaccine against malignant mesothelioma that elicited complete and long-lasting protection against malignancy, while curing pre-existing tumors in mouse models. Read More

HONG KONG – Samsung Bioepis Co. Ltd., the biopharmaceutical arm of the South Korean conglomerate, is looking to take high-quality biosimilars global in just two years. For the company, which is expanding its footprint in that competitive space, it all comes down to 2016. Read More

HONG KONG – This year has been a good one for biopharma companies in China, many of which are combining a growing market with stronger R&D pipelines, some government support and more tightly controlled expenses and are turning out some positive results. Read More